Cited by 23Photodynamic Therapy Research StudiesPorphyrin Metabolism and DisordersPorphyrin and Phthalocyanine Chemistry

Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug

Open access
Curnow, Alison, Perry, Alexis, Wood, Mark·2019·Photodiagnosis and Photodynamic Therapy

Abstract

BACKGROUND: Photodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of cancers and precancers. It is particularly useful in its topical form in dermatology but improvement of efficacy is required to widen its application. METHODS: An ester between aminolaevulinic acid (ALA) and CP94 was synthesised (AP2-18) and experimentally evaluated to determine whether protoporphyrin IX (PpIX)-induced PDT effectiveness could be improved. A biological evaluation of AP2-18 was conducted in cultured human primary cells with both PpIX fluorescence and cell viability (as determined via the neutral red assay) being assessed in comparison to the PpIX prodrugs normally utilised in clinical practice (aminolaevulinic acid (ALA) or its methyl ester (MAL)) either administered alone or with the comparator iron chelator, CP94. RESULTS: No significant dark toxicity was observed in human lung fibroblasts but AP2-18 significantly increased PpIX accumulation above and beyond that achieved with ALA or MAL administration +/- CP94 in both human dermal fibroblasts and epithelial squamous carcinoma cells. On light exposure, the combined hydroxypyridinone iron chelating ALA prodrug AP2-18 generated significantly greater cytotoxicity than any of the other treatment parameters investigated when the lowest concentration (250 μM) was employed. CONCLUSIONS: Newly synthesised AP2-18 is therefore concluded to be an efficacious prodrug for PpIX-induced PDT in these dermatologically relevant human cells, achieving enhanced effects at lower concentrations than currently possible with existing pharmaceuticals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pdpdt.2018.12.005

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

9 of the 82 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [3]Vallejo-Torres L. Morris S. Kinge J. Poirier V. Verne J.J. Public Health 36 2014 140 148 23554510
  2. [22]Tyrrell J. Morton C. Campbell S. Curnow A. Comparison of PpIX accumulation and destruction during methyl-aminolevulinate photodynamic therapy (MAL-PDT) of skin tumours located at acral and non-acral sites Br. J. Dermatol. 164 2011 1362 1368 21564050

Cited by

Sorted by citations

Authors
Curnow, A., Perry, A., & Wood, M.
Affiliations
University of Exeter (GB)
Corresponding author
Curnow, Alison
Venue
Photodiagnosis and Photodynamic Therapy
Publisher
Elsevier BV
Published
2019-03
Volume
25
Pages
157-165
ISSN
1572-1000 (ISSN-L)
OpenAlex
W2904634565
Cited by
22
References
82
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 3
FWCI
2.07
Type
journal article
Language
en
Open access
Locations
  • Photodiagnosis and Photodynamic Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
Funders
  • Proximity to Discovery grant from the Medical Research Council, UK
  • Killing Cancer, UK
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
  • Physical Sciences › Materials Science › Materials Chemistry › Porphyrin and Phthalocyanine Chemistry
Keywords
photodynamic therapy, iron chelation, protoporphyrin IX, hydroxypyridinone, topical photodynamic therapy, dermal fibroblasts, cytotoxicity, dark toxicity
MeSH terms
Aminolevulinic Acid, Cell Survival, Humans, Iron Chelating Agents, Photochemotherapy, Prodrugs, Protoporphyrins, Pyridones, Skin Neoplasms, Photosensitizing Agents, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review